Oxygen Therapeutics: Perfluorocarbons and Blood Substitute Safety

Critical Care Clinics

Volumn 25, Issue 2, 2009, Pages 399-414

  Cohn, Claudia S ^a   Cushing, Melissa M ^b  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Blood substitute; Hemoglobin based oxygen carrier (HBOC); Perfluorocarbons (PFC)

Indexed keywords

APEXPHP; ARTIFICIAL BLOOD; BLOOD SUBSTITUTE; FLUOROCARBON; FLUOSOL DA; HEMOGLOBIN; HEMOGLOBIN GLUTAMER 200; OXYCYTE; OXYFLUOR; PERFLUORODECALIN PLUS PERFLUORO N (4 METHYLCYCLOHEXYL)PIPERIDINE; PERFLUOROOCTYL BROMIDE; PERFTORAN; POLYMERIZED HEMOGLOBIN; UNCLASSIFIED DRUG;

ANEMIA; BLEEDING; BLOOD SUBSTITUTION; CLINICAL TRIAL; DRUG SAFETY; DYSPHAGIA; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEMORRHAGIC SHOCK; HUMAN; HYPOTENSION; IMMUNOPATHOLOGY; INFECTION RISK; LUNG DISEASE; METHEMOGLOBINEMIA; NEUROTOXICITY; OXIMETRY; OXYGEN AFFINITY; OXYGEN DISSOCIATION CURVE; OXYGEN TRANSPORT; PANCREATITIS; PRION DISEASE; PRIORITY JOURNAL; RESUSCITATION; REVIEW; SEPSIS; SIDE EFFECT; STROKE; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

BLOOD SUBSTITUTES; ERYTHROCYTE TRANSFUSION; FLUOROCARBONS; HUMANS; OXYGEN;

EID: 63049083721     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccc.2008.12.007     Document Type: Review

References (46)

1. Amberson W.R., Mulder A.G., Steggerda F.R., et al. Mammalian life without red blood corpuscles. Science 78 (1933) 106-107
2. Brandt J.L., Frank N.R., Lichtman H.C., et al. The effects of hemoglobin solutions on renal functions in man. Blood 6 (1951) 1152-1158
3. Miller J.H., and McDonald R.K. The effect of hemoglobin on renal function in the human. J Clin Invest 30 (1951) 1033-1040
4. Riess J.G. Understanding the fundamentals of perfluorocarbons and perfluorocarbon emulsions relevant to in vivo oxygen delivery. Artif Cells Blood Substit Immobil Biotechnol 33 (2005) 47-63
5. Clark Jr. L.C., and Gollan F. Survival of mammals breathing organic liquids equilibrated with oxygen at atmospheric pressure. Science 152 (1966) 1755-1756
6. Gould S.A., Rosen A.L., Sehgal L.R., et al. Fluosol-DA as a red-cell substitute in acute anemia. N Engl J Med 314 (1986) 1653-1656
7. Bucala R., Kawakami M., Cerami A., et al. Cytotoxicity of a perfluorocarbon blood substitute to macrophages in vitro. Science 220 (1983) 965-967
8. Riess J.G. Perfluorocarbon-based oxygen delivery. Artif Cells Blood Substit Immobil Biotechnol 34 (2006) 567-580
9. Spahn D.R., Waschke K.F., Standl T., et al. Use of perflubron emulsion to decrease allogeneic blood transfusion in high-blood-loss non-cardiac surgery: results of a European phase 3 study. Anesthesiology 97 (2002) 1338-1349
10. Niiler E. Setbacks for blood substitute companies. Nat Biotechnol 20 (2002) 962-963
11. Riess J.G., and Krafft M.P. Fluorocarbon emulsions as in vivo oxygen delivery systems: background and chemistry. In: Winslow R.M. (Ed). Blood substitutes. 1st edition (2006), Academic Press, New York 259-276
12. Maevsky E., Ivanitsky G., Bogdanova L., et al. Clinical results of perftoran application: present and future. Artif Cells Blood Substit Immobil Biotechnol 33 (2005) 37-46
13. Verdin-Vasquez R.C., Zepeda-Perez C., Ferra-Ferrer R., et al. Use of perftoran emulsion to decrease allogeneic blood transfusion in cardiac surgery: clinical trial. Artif Cells Blood Substit Immobil Biotechnol 34 (2006) 433-454
14. Hess J.R., MacDonald V.W., Brinkley W.W., et al. Systemic and pulmonary hypertension after resuscitation with cell-free hemoglobin. J Appl Phys 74 (1993) 1769-1778
15. Hess J.R. Blood substitutes for surgery and trauma: efficacy and toxicity issues. BioDrugs 12 (1999) 81-90
16. Ortegon D.P., Davis M.R., Dixon P.S., et al. The polymerized bovine hemoglobin-based oxygen-carrying solution (HBOC-201) is not toxic to neural cells in culture. J Trauma 53 (2002) 1068-1072
17. Cole D.J., Nary J.C., Reynolds L.W., et al. Experimental subarachnoid hemorrhage in rats: effect of intravenous alpha-alpha diaspirin crosslinked hemoglobin on hypoperfusion and neuronal death. Anesthesiology 87 (1997) 1486-1493
18. Kim H.W., and Greenburg A.G. Artificial oxygen carriers as red blood cell substitutes: a selected review and current status. Artif Organs 28 (2004) 813-828
19. Winslow R.M. Current status of oxygen carriers ('blood substitutes'): 2006. Vox Sang 91 (2006) 102-110
20. Hughes Jr. G.S., Francome S.F., Antal E.J., et al. Hematologic effects of a novel hemoglobin-based oxygen carrier in normal male and female subjects. J Lab Clin Med 126 (1995) 444-451
21. Jahr J.S., Walker V., Manoochehri K., et al. Blood substitutes as pharmacotherapies in clinical practice. Curr Opin Anaesthesiol 20 (2007) 325-330
22. Warshaw A.L., and O'Hara P.J. Susceptibility of the pancreas to ischemic injury in shock. Ann Surg 188 (1978) 197-201
23. Henkel-Honke T., and Oleck M. Artificial oxygen carriers: a current review. AANA J 75 (2007) 205-211
24. Kleinhans H., Mann O., Schurr P.G., et al. Oxygen radical formation does not have an impact in the treatment of severe acute experimental pancreatitis using free cellular hemoglobin. World J Gastroenterol 12 (2006) 2914-2918
25. Silverman T, Landow L, Ko HS. et al. Review of publicly available reports of adverse events associated with HBOCs. Office of Blood Research and Review, CBER, FDA. 2008.
26. Ali A.A., Ali G.S., Steinke J.M., et al. Co-oximetry interference by hemoglobin-based blood substitutes. Anesth Analg 92 (2001) 863-869
27. Griffiths E., Cortes A., Gilbert N., et al. Haemoglobin-based blood substitutes and sepsis. Lancet 345 (1995) 158-160
28. Will R.G., Ironside J.W., Zeidler M., et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 347 (1996) 921-925
29. Laccetti A., Bagai J., Gawryl M.S., et al. Hemopure's process demonstrates TSE and viral clearance. Dev Biol (Basel) 120 (2005) 35-36
30. Burdick M.D., Pifat D.Y., Petteway Jr. S.R., et al. Clearance of prions during plasma protein manufacture. Transfus Med Rev 20 (2006) 57-62
31. Shepherd A.P., and Steinke J.M. Co-oximetry interference by perflubron emulsion: comparison of hemolyzing and nonhemolyzing instruments. Clin Chem 44 (1998) 2183-2190
32. Cuignet O.Y., Wood B.L., Chandler W.L., et al. A second-generation blood substitute (perfluorodichlorooctane emulsion) generates spurious elevations in platelet counts from automated hematology analyzers. Anesth Analg 90 (2000) 517-522
33. Ma Z., Monk T.G., Goodnough L.T., et al. Effect of hemoglobin- and perflubron-based oxygen carriers on common clinical laboratory tests. Clin Chem 43 (1997) 1732-1737
34. Moreira P.L., Lansden C.C., Clark T.L., et al. Effect of Hemopure on prothrombin time and activated partial thromboplastin time on seven coagulation analyzers. Clin Chem 43 (1997) 1792
35. Leytin V., Mazer D., Mody M., et al. Hemolink, an o-raffinose cross-linked haemoglobin-based oxygen carrier, does not affect activation and function of human platelets in whole blood in vitro. Br J Haematol 120 (2003) 535-541
36. James M.F., Potgieter H.E., Ellis P., et al. The effect of Hemopure on coagulation in clinically relevant concentrations. Anesth Analg 99 (2004) 1593-1597 table of contents
37. Jahr J.S., Lurie F., Gosselin R., et al. Effects of a hemoglobin-based oxygen carrier (HBOC-201) on coagulation testing. Clin Lab Sci 13 (2000) 210-214
38. Shirey R.S., Lewin M., Ness P.M., et al. Hemoglobin-based oxygen carriers: effect on serologic pretransfusion testing. Transfusion 44 (2004) 122A
39. Wolthuis A., Peek D., Scholten R., et al. Effect of the hemoglobin-based oxygen carrier HBOC-201 on laboratory instrumentation: cobas integra, chiron blood gas analyzer 840, Sysmex SE-9000 and BCT. Clin Chem Lab Med 37 (1999) 71-76
40. Kazmierczak S.C., Catrou P.G., Best A.E., et al. Multiple regression analysis of interference effects from a hemoglobin-based oxygen carrier solution. Clin Chem Lab Med 37 (1999) 453-464
41. Callas D.D., Clark T.L., Moreira P.L., et al. In vitro effects of a novel hemoglobin-based oxygen carrier on routine chemistry, therapeutic drug, coagulation, hematology, and blood bank assays. Clin Chem 43 (1997) 1744-1748
42. Jahr J.S., Osgood S., Rothenberg S.J., et al. Lactate measurement interference by hemoglobin-based oxygen carriers (Oxyglobin, Hemopure, and Hemolink). Anesth Analg 100 (2005) 431-436
43. Sakai H., Tomiyama K., Masada Y., et al. Pretreatment of serum containing hemoglobin vesicles (oxygen carriers) to prevent their interference in laboratory tests. Clin Chem Lab Med 41 (2003) 222-231
44. Mullon J., Giacoppe G., Clagett C., et al. Transfusions of polymerized bovine hemoglobin in a patient with severe autoimmune hemolytic anemia. N Engl J Med 342 (2000) 1638-1643
45. Natanson C., Kern S.J., Lurie P., et al. Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis. JAMA 299 (2008) 2304-2312
46. Fergusson D.A., and McIntyre L. The future of clinical trials evaluating blood substitutes. JAMA 299 (2008) 2324-2326